Business Context and Reporting Period
This Form 6-K filing by MDxHealth SA covers the month of February 2026, with the report dated February 11, 2026. The filing primarily discloses two significant corporate transactions: the completed acquisition of Exosome Diagnostics, Inc. and an amendment to the earnout agreement regarding the prior GPS acquisition.
Key Financial Metrics and Transactions
The filing details specific financial terms for recent acquisitions but does not provide the Company's standalone revenue, profit, cash flow, or liquidity metrics for the reporting period.
- Exosome Diagnostics Acquisition: Closed on September 15, 2025. The aggregate purchase price is up to $15 million. Payment terms include approximately $5 million in stock at closing, with $2.5 million payable annually over the following four years (50% cash, 50% cash or stock at the Company's discretion).
- GPS Acquisition Earnout Amendment: Signed on January 9, 2026, with Exact Sciences. Remaining earnout payments are deferred and extended: $15.0 million in 2026, $18.0 million in 2027, and $21.5 million in 2028.
- Equity Consideration: In exchange for the GPS earnout amendment, MDxHealth agreed to issue warrants to Exact Sciences exercisable into 3 million shares of common stock at an exercise price of $5.265 per warrant.
Material Changes Versus Prior Period
The filing does not provide comparative financial data (e.g., revenue or net income) for the current period versus the prior comparable period. The material changes disclosed are structural and contractual:
- Expansion of the Company's portfolio through the acquisition of Exosome Diagnostics, including the ExoDx test and a CLIA-certified clinical laboratory.
- Restructuring of future cash outflows related to the GPS acquisition, pushing significant payments into 2026, 2027, and 2028.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or a specific risk factor section. However, the following contingencies and unusual items are noted:
- Payment Contingencies: Future payments for the Exosome Diagnostics acquisition are subject to certain conditions.
- Discretionary Payment Terms: The Company retains discretion to pay 50% of the annual Exosome Diagnostics earnout in either cash or stock.
- Pro Forma Data: The filing references unaudited pro forma condensed combined financial statements for the year ended December 31, 2024, and the six months ended June 30, 2025, filed as Exhibit 99.2, though the specific figures are not included in this text.
Investor Verification Checklist
- Verify the specific conditions attached to the $2.5 million annual payments for the Exosome Diagnostics acquisition.
- Review Exhibit 99.2 for the unaudited pro forma combined financial statements to assess the impact of the Exosome Diagnostics acquisition on the Company's balance sheet and operations.
- Confirm the dilution impact of the 3 million warrants issued to Exact Sciences.
- Assess the Company's liquidity position to ensure it can meet the $15.0 million earnout payment due in 2026.